FDA Approves Tebentafusp-tebn for Unresectable or Metastatic Uveal Melanoma

On Wednesday, January 26, 2022, the U.S. Food and Drug Administration (FDA) approved tebentafusp-tebn for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma. 

Read Immunocore's announcement.

Posted 1/26/2022